NCT01395849已完成不适用
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,116
- 主要终点
- The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate
研究概览
简要总结
The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must use fluticasone and salmeterol for the first time
排除标准
- •Patients with hypersensitivity to salmeterol and fluticasone
- •Patients with infection which salmeterol and fluticasone is not effective
- •Patients with deep mycosis
研究组 & 干预措施
Patients prescribed fluticasone and salmeterol
Patients with asthma prescribed fluticasone and salmeterol during study period
干预措施: Salmeterol and Fluticasone (Drug)
结局指标
主要结局
The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate
时间窗: 6 months
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)Respiratory DisordersNCT01395862GlaxoSmithKline1,001
已完成
不适用
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in JapanLung Diseases, InterstitialNCT04325217Boehringer Ingelheim586
已完成
不适用
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism TreatmentAtaxiaNCT01428531GlaxoSmithKline200
已完成
4 期
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%Conjunctivitis, Seasonal AllergicConjunctivitis, Giant PapillaryInflammationNCT01437982Bausch & Lomb Incorporated140
已完成
不适用
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular CarcinomaHepatocellular CarcinomaNCT02269995Eisai Co., Ltd.300